VALBIOTIS
29.3.2022 07:37:05 CEST | Business Wire | Press release
Regulatory News:
Valbiotis (FR0013254851 - ALVAL, PEA-SME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, announces the positive results of its clinical study on the bioavailability and mode of action of TOTUM•070 against hypercholesterolemia.
This innovative protocol, involving 10 healthy volunteers, has first confirmed the presence of 22 metabolites2 of interest in the serum3 of volunteers. The analyses were conducted following oral administration of the clinical dose of 5g of TOTUM•070, used also in the Phase II HEART study. Most of the 22 metabolites are already known for their activity on metabolism. Mode of action analyses then demonstrated, among other things, two effects of TOTUM•070 on human liver cells: inhibition of the cholesterol synthesis pathway and inhibition of cholesterol storage in hepatocytes. These two effects on cholesterol in the liver, which is one of the main metabolic organs, speak in favor of TOTUM•070’s potential against hypercholesterolemia. Following on from these positive results, Valbiotis will announce the outcome of its Phase II HEART clinical efficacy study in the second quarter of 2022, as planned. Its primary endpoint is the reduction of blood LDL-cholesterol.
Pascal SIRVENT, Director of Discovery and Preclinical and Translational Research and Member of the Board of Directors, states: “For the first time, this clinical study has evaluated the bioavailability and hepatic mode of action of TOTUM•070 in humans. The results live up to our expectations: we can confirm that TOTUM•070 contains many metabolites of interest for regulating cholesterol. Most importantly, the results show that these metabolites are bioavailable in humans and have two significant effects on the regulation of cholesterol in the cells of the human liver, one of the main metabolic organs. These novel clinical data build on the positive preclinical results presented in 2021 and pave the way for further mode-of-action investigations in the liver. Above all, they confirm the potential of TOTUM•070 against hypercholesterolemia in humans, pending the imminent results of our Phase II clinical efficacy study.”
Murielle CAZAUBIEL, Director of Medical, Regulatory and Industrial Affairs and Member of the Board of Directors, adds: “During this clinical study on TOTUM•070, we used an innovative methodology adapted to our plant-based active substances that combines metabolomics and mode of action, which is now producing results. This is a positive clinical development and a very encouraging sign while we wait for the Phase II HEART clinical efficacy results, which will become available in the second quarter of 2022.”
Results of the clinical study on bioavailability and mode of action
This study was conducted on 10 healthy volunteers in an open-label setting and followed a protocol combining metabolomics and mode of action, designed and implemented by Clinic’n’Cell. Professor Gisèle PICKERING, coordinator of the Clinical Investigation Center of the Clermont-Ferrand University Hospital, was Principal Investigator4 .
Metabolomic analysis consists of characterizing the metabolites of an active substance in serum, i.e., the molecules derived from this active substance following their intestinal absorption and passage into the blood. After a single oral dose of 5g of TOTUM•070, which is the clinical daily dose, used also in the HEART clinical study (see below), analysis of the volunteers’ serum confirmed the presence of 22 metabolites of interest, the majority of which are known to have a biological activity on metabolism. Kinetic measurements validated good bioavailability of these metabolites in serum within three hours of oral TOTUM•070 intake.
In a second step, the serum collected from volunteers after oral intake of 5g of TOTUM•070 – a serum rich in active metabolites from TOTUM•070 – was used to conduct in vitro tests on human liver cells exposed to massive lipid intake. In this context of “lipotoxic stress”, the volunteers’ serum exerted two major effects on these human liver cell lines: inhibition of the de novo cholesterol synthesis pathway1 and inhibition of cholesterol storage. It also showed no toxicity.
All analyses were conducted with a double control: cell cultures with and without lipotoxic stress, then with and without serum enriched in active metabolites.
Upcoming publication of the Phase II clinical results of TOTUM•070 on hypercholesterolemia
The Phase II HEART clinical trial results will be announced in the second quarter of 2022. This multi-center study will evaluate the efficacy of TOTUM•070 in reducing blood LDL-cholesterol levels versus placebo, in 120 volunteers with mild to moderate untreated hypercholesterolemia. These results will be decisive for the marketing of TOTUM•070, an innovative 100% plant-based active substance containing neither phytosterols nor red yeast rice, and for its positioning as a reference non-drug option against LDL-cholesterol.
About Valbiotis
Valbiotis is a Research & Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases in response to unmet medical needs.
Valbiotis has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of health nutrition products designed to reduce the risk of major metabolic diseases, relying on a multi-target strategy enabled by the use of plant-based terrestrial and marine resources.
Its products are intended to be licensed to players in the health sector.
Created at the beginning of 2014 in La Rochelle, the Company has forged numerous partnerships with leading academic centers. The Company has established three sites in France – Périgny, La Rochelle (17) and Riom (63) – and a subsidiary in Quebec City (Canada).
Valbiotis is a member of the "BPI Excellence" network and has been recognized as an "Innovative Company" by the BPI label. Valbiotis has also been awarded "Young Innovative Company" status and has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). Valbiotis is a PEA-SME eligible company.
For more information about Valbiotis, please visit: www.valbiotis.com
Name: Valbiotis
ISIN Code: FR0013254851
Ticker symbol: ALVAL
EnterNext© PEA-PME 150
This press release contains forward-looking statements about Valbiotis’ objectives. Valbiotis considers that these projections are based on rational hypotheses and the information available to Valbiotis at the present time. However, in no way does this constitute a guarantee of future performance, and these projections may be affected by changes in economic conditions and financial markets, as well as certain risks and uncertainties, including those described in the Valbiotis Universal Registration Document approved by the French Financial Markets Regulator (AMF) on July 27, 2021 (application number R 21-039). This document is available on the Company’s website (www.valbiotis.com
).
This press release and the information it contains do not constitute an offer to sell or subscribe, or a solicitation to purchase or subscribe to Valbiotis’ shares or financial securities in any country.
1
Cholesterol can be brought by food or produced by the body itself ("de novo
synthesis").
2
Molecules derived from TOTUM•070, following their intestinal absorption and passage into the blood.
3
The fraction of blood remaining after all blood cells (red blood cells, leukocytes, platelets) and fibrinogen (a protein involved in clotting) have been removed.
4
ID-RCB: 2021-A01211-40
View source version on businesswire.com: https://www.businesswire.com/news/home/20220328005495/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Future Health Launches Academy to Translate Life Sciences Advances Into Strategic Action18.11.2026 15:37:00 CET | Press release
Future Health Academy will build knowledge and connect expertise among health and life sciences professionals in Abu Dhabi and internationally. The Academy will support two-way knowledge exchange, bringing global expertise to Abu Dhabi while creating opportunities to share Abu Dhabi’s knowledge, expertise and innovation with the world. Inaugural course brought together senior leaders from government, healthcare, research, and industry with local and international scientific experts. Future Health - A Global Initiative by Abu Dhabi has launched the Future Health Academy as part of its year-round programme, designed to build knowledge, connect expertise and create opportunities for collaboration among health and life sciences professionals in Abu Dhabi and internationally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118051527/en/ The Future Health Academy will build knowledge and connect expertise among health and life s
Soracom Launches Physical AI Suite, Bringing Secure Connectivity and Remote Operations to Robots and Autonomous Machines18.11.2026 15:30:00 CET | Press release
Soracom suite combines existing platform services for physical AI, available worldwide Soracom, Inc. (TSE: 147A), a cloud-native IoT platform providing connectivity, cloud integration, and AI services for the Internet of Things, today announced Soracom Physical AI Suite, a set of Soracom platform services combined to connect, protect, and manage physical AI systems such as robots, autonomous mobile machines, and industrial equipment. Soracom Physical AI Suite is the company's second suite, following Soracom Automotive Suite announced in July 2026. Each suite brings together Soracom platform services commonly used for a particular type of deployment, organizing them into a single system. A team starting a new deployment begins from that system instead of selecting and assembling services one at a time. The suite is designed for companies that develop or deploy robots and other physical AI systems and for companies that operate connected equipment in industries including manufacturing, l
Variational Raises $110M Series B at $1.5B Valuation To Scale On-Chain Access To Global Markets18.11.2026 15:23:00 CET | Press release
The raise follows the rapid growth of swaps, Variational’s new instrument bringing liquidity from traditional finance on-chain. Variational, a protocol for on-chain derivatives trading, has announced a $110M Series B raise at a $1.5B valuation led by Bain Capital Crypto with support from Dragonfly, HSG, Peak XV, 50T Funds, and more. Since launching in early 2025, the platform has processed $475B+ in trading volume and accumulated $1.3B+ in open interest across 100k+ accounts. More than half of daily volume on the platform is now on traditional markets. The raise will fund the platform’s continued growth, allowing Variational to list hundreds more markets and lift open interest caps that traders increasingly hit. Omni, a trading platform built on Variational, offers leveraged trading on 550+ crypto and traditional markets. Unlike other on-chain trading platforms, Omni aggregates liquidity from both traditional and on-chain markets. This model allowed the platform to launch “swaps” in Se
Xsolla Connects Players, Brands, and Video Game Audiences Through Rewarded Engagement18.11.2026 15:00:00 CET | Press release
Players Can Choose Their Quests, Developers Get Measurable Results From Their Games, and Advertisers Get Verified Insight From Players Who Choose to Share Xsolla (USA), Inc., a global commerce company, announces Xsolla Ads, a rewarded marketing solution connecting brands with game audiences through quests players choose to take part in. Studios generate revenue beyond player purchases while brands drive measurable engagement, acquisition, and purchases. Players choose which campaigns to participate in and which rewards to receive. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117947414/en/ Graphic: Xsolla Players see Xsolla Ads where they already are, including the Xsolla App, game web shops, branded pages on Xsolla, Xsolla Choice surveys, and an opt-in Offerwall. Quests are triggered by game events, such as reaching a new level or season, so studios connect campaigns to what players already do in their games. Completed
Sila Inks Long-Term Offtake Deal with Panasonic Energy to Power Domestic Battery Production18.11.2026 15:00:00 CET | Press release
Agreement to deliver Sila’s Titan Silicon® Si/C anode to Panasonic’s U.S. manufacturing sites, fortifying domestic battery supply chain resilience and advanced technology capabilities. Sila, a leading battery technology and materials company, today announced a commercial offtake agreement with Panasonic Energy Corporation of North America. The multi-year agreement is part of a long-term commercial relationship with the potential for over $1 billion of offtake over time. Sila will supply its proprietary Titan Silicon® silicon-carbon (Si/C) anode material from its Moses Lake, Washington plant to power Panasonic battery cells. The partnership is also expected to support significant manufacturing and construction job creation in the United States. With Sila’s U.S.-based anode production underpinned by proprietary American technology and know-how, Panasonic and its OEM customers gain a clearer path toward a more secure, resilient, and sustainable domestic supply chain. This press release fe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
